These studies accelerated the clinical approval of both drugs for the treatment of therapy-resistant, advanced-stage, metastatic pediatric and adult Trk-fused gene-positive cancers, and these drugs continue to elicit profound durable responses (see clinical trials NCT05192642, NCT02650401, NCT04589845, and NCT02568267) [8,9,10,11,12,13]. The gene discussed is NTRK1; the disease is cancer.